PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis

PROVO, Utah, March 10, 2015 /PRNewswire/ -- Tute Genomics, pioneer in affordable, accurate and rapid genome interpretation, has been selected by next-generation sequencing company PrimBio Research Institute to be its primary provider of whole exome and targeted gene panel interpretation.

PrimBio, a certified Life Technologies Ampliseq Exome sequencing provider, has adopted the most current technologies to support the work of experts on the front lines of genetic research. The company offers two types of exome sequencing services: 1) Targeted Exome and 2) Ampliseq Exome sequencing. In addition to whole exome interpretation, PrimBio will also be using Tute's services for six of their targeted gene panel offerings (Cancer Hotspot Panel, Comprehensive Cancer Panel, Inherited Disease Panel, BRCA1 and BRCA2 Panel, Breast Cancer Panel, and Colorectal Cancer Panel). PrimBio's experienced and dedicated staff has built a reputation for reliable and fast services including library preparation, sequencing, alignment and variant calling in both the United States and globally.

"Genome sequencing for research & discovery is at the heart of what we do," commented PrimBio Founder, Diana Ye. "This partnership with Tute Genomics is a win-win for our current and future clients who will benefit from the comprehensive genome analytics and integrated solution that we can now provide."

Tute Genomics provides powerful tools for genomic insights. The web-based platform is adaptable to both whole genome and targeted gene panel applications. With the Tute Genomics API, sequencing service providers can now directly stream next generation sequencing data to Tute and obtain fully annotated results as well as perform case controlled analysis in a seamless fashion. Tute Genomics' robust platform includes annotations from more than 200 sources along with customizable data filtration.

"Our mission is to make precision medicine a reality by enabling researchers and clinicians to utilize human genome data for scientific discovery and individualized treatment," remarked Reid Robison, CEO at Tute Genomics. "Our partnership with PrimBio is an example of a fully integrated pipeline with sample to report capability, to accelerate genomics research and enable personalized medicine."

This new partnership allows for a fully streamlined sample-in, report-out innovation, made possible by next-generation sequencing from PrimBio, combined with interpretation & analytics software from Tute Genomics. This integration helps both organizations continue to push the boundaries of genetic research, ultimately developing clinical applications that will herald a new era in genome-guided medicine.

About PrimBio Research Institute

PrimBio Research Institute is a full-service genetics laboratory, with next-generation sequencing capabilities, committed to providing innovative technologies and platforms for your genome sequencing needs. PrimBio was founded in 2011 to advance genomic research by providing high quality results with fast turnaround times and competitive prices. To learn more, visit www.primbioresearch.com.

About Tute Genomics

Tute Genomics is a Utah-based company that is powering the world's genomic knowledge with a cloud-based solution for precision, genome-guided medicine.  Tute provides a clinical genome interpretation platform that helps researchers identify disease genes and biomarkers, and assists clinicians/labs with genetic diagnosis and personalized therapeutics. Tute is built on the expertise that developed ANNOVAR, the most widely used genome annotation and interpretation technology with over 1000 scientific citations. The genome revolution is here, and Tute envisions a future where genome sequencing is part of routine clinical care. Tute integrates genomic data into medical records to give doctors and patients alike access to genetic information at their fingertips where it is most useful and actionable. Genomics is changing healthcare as we know it, and Tute is helping to shape the future of medicine: unlocking the genome, personalizing treatment, and powering discovery. To learn more please visit www.tutegenomics.com and follow us on twitter @TuteGenomics.

Contact:

Mary Brown
858-779-4363
Email

SOURCE Tute Genomics

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.